CA2675980A1 — Use of dast for treatment of cancers with acquired resistance to kit inhibitors
Assigned to Bayer Healthcare LLC · Expires 2008-07-24 · 18y expired
What this patent protects
The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST ( 4{4-[3-(4-chloro-3- trifluoromethylphenyf)-ureid o]-3-fluorophenoxy}-pyridine -2-carboxylic acid methyl…
USPTO Abstract
The present invention provides compositions and uses thereof for treating cancers which have acquired resistance to a KIT inhibitor by administering effective amounts of DAST ( 4{4-[3-(4-chloro-3- trifluoromethylphenyf)-ureid o]-3-fluorophenoxy}-pyridine -2-carboxylic acid methylamide.)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.